Equity Overview
Price & Market Data
Price: $1.25
Daily Change: -$0.02 / 1.60%
Range: $1.25 - $1.28
Market Cap: $13,386,250
Volume: 3,822
Performance Metrics
1 Week: 12.17%
1 Month: 11.21%
3 Months: -39.72%
6 Months: -71.59%
1 Year: -70.85%
YTD: -58.52%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.